The TARDIS assay could be used to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.
Investigators in Austria studied overall survival in 914 patients diagnosed with mRCC from July 1985 to September 2020.
Strategies such as booster doses appear warranted in this population.
Investigators examined outcomes of robotic radiosurgery in patients with lung, visceral, and lymph node metastases from renal cell carcinoma.
Investigators describe the type and frequency of adverse reactions and how clinicians managed them.
Patients with poor performance status have been excluded from pivotal trials on metastatic renal cell carcinoma.